Compare Incyte Corporation (INCY) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Iron Mountain Inc — how do they compare? Incyte Corporation trades at $120.8 (market cap $24.54B), while Iron Mountain Inc trades at $123.56 (market cap $36.44B). The key difference: Iron Mountain Inc is the larger of the two by market cap, and Iron Mountain Inc pays a 2.82% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | IRM | |
|---|---|---|
Market Cap | $24.54B | $36.44B |
Sector | Health | Real Estate |
52-Week High | $129.93 | $133.06 |
52-Week Low | $81.61 | $78.86 |
Enterprise Value | $20.04B | $55.85B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Iron Mountain (IRM) trades at $124.67, up 2.56% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $6.90B in 2025, though net margins compressed to 2.09%. The stock is supported by a 65% analyst buy rating and a $141.50 consensus target, with institutional interest highlighted by recent purchases. Key risks include high debt levels, with a debt-to-asset ratio of 79.04% in 2025.
Outlook remains mixed; robust data center growth and dividend yield near 2.8% offer upside, but elevated valuation (P/E 86.8) and persistent negative shareholder equity warrant caution. Earnings momentum from Q2 2026 beat provides near-term support, yet debt servicing and competitive pressures pose headwinds for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
